Results 231 to 240 of about 179,831 (305)

A Case for Anti‐IgE Vaccination

Allergy, EarlyView.
ABSTRACT Immunoglobulin E (IgE) plays a central role in allergic diseases by binding to the high‐affinity receptor FcεRI on mast cells and basophils, where allergen‐induced crosslinking triggers potent inflammatory responses. Various mechanisms by which IgE responses are generated and functionally regulated remain elusive despite many years of research.
Paul Engeroff, Zahra Gharailoo, Monique Vogel, Martin F. Bachmann   +3 more
wiley   +1 more source

Commentary: is trogocytosis relevant for chimeric antigen receptor-T cells? [PDF]

Oncologist
Toolabi B, Whiteheart SW, Munker R.
europepmc   +1 more source

Bridging practices prior to brexucabtagene autoleucel for mantle cell lymphoma in the United Kingdom: An analysis of modality, response, toxicity and survival

British Journal of Haematology, EarlyView.
Summary Bridging therapy (BT) prior to brexucabtagene autoleucel (brexu‐cel) in mantle cell lymphoma (MCL) is supported by limited evidence. Here, we report BT modality and outcome in 176 patients at 15 centres in the United Kingdom. BT was delivered to 90% (158/176), the majority receiving standard chemotherapy +/− radiotherapy (53%) (SD chemo +/− RT)
Maeve A. O'Reilly, William Wilson, Bernard Maybury, Andrea Kuhnl, Claire Roddie, Ben Uttenthal, Rod Johnson, Rajesh Alajangi, Thomas Creasey, Ahmed Abdulgawad, Carlos Gonzalez Arias, Sunil Iyengar, Graeme Ferguson, Katerina Panopoulou, Alison Delaney, Angharad Pryce, Lourdes Rubio, Ceri Jones, Jonathan Lambert, Shweta Gupta, Amrith Mathew, Shenbagaram Kasivisvanathan, Olateni Awofisayo, Shreyas Hanmantgad, Graham P. Collins, Caroline Besley, Frances Seymour, Robin Sanderson, Sridhar Chaganti   +28 more
wiley   +1 more source

Diurnal rhythm in chimeric antigen receptor T cell effectiveness in an observational study of 715 patients. [PDF]

JCI Insight
Lyons PG, Gill E, Kumar P, Beasley M, Park-Egan B, Lokhandwala ZA, Lebold KM, Hayes-Lattin B, Hough CL, Singh N, Hazan G, Mok H, Huss JM, McEvoy CA, Haspel JA.   +14 more
europepmc   +1 more source

Circulating tumour cells (CTCs) in haematological malignancies: Advances in biology and clinical relevance with a focus on multiple myeloma

British Journal of Haematology, EarlyView.
Spatial heterogeneity limits the sensitivity of bone marrow biopsies, resulting in false‐negative findings. Circulating tumour cells (CTCs) provide a systemic, stratified monitoring approach, using flow cytometry for high tumour burden and EuroFlow or allele‐specific oligonucleotide PCR (ASO‐PCR) for minimal residual disease to enable early relapse ...
Chin‐Mu Hsu, Jui‐Feng Hsu, Jee‐Fu Huang, Yi‐Chang Liu   +3 more
wiley   +1 more source

Vascular inflammation in patients undergoing anti-CD19 chimeric antigen receptor-T cells for haematologic malignancies: a call for cardiovascular surveillance. [PDF]

Eur Heart J
Camilli M, Guarneri A, Leccisotti L, Ballacci F, Viscovo M, Galli E, Maggio L, Tinti L, Lamendola P, Hohaus S, Sica S, Sorà F, Chiusolo P, Lanza GA, Liuzzo G, Burzotta F, Giordano A, Crea F, Lombardo A, Minotti G.   +19 more
europepmc   +1 more source

Emerging role of lisocabtagene maraleucel chimeric antigen receptor-T cell in nodal and gastrointestinal follicular lymphoma. [PDF]

World J Gastroenterol
Watanabe T.
europepmc   +1 more source

Efficacy of immune checkpoint inhibitors in paediatric, adolescent and young adults with primary refractory or relapsed classical Hodgkin lymphoma: A national multicentre real‐world study

British Journal of Haematology, EarlyView.
Summary Classical Hodgkin lymphoma (cHL) is the most frequent lymphoma in children, adolescents and young adults (CAYA). Despite therapeutic advances, around 15% of patients relapse or have refractory (R/R) disease. Conventional salvage regimens remain effective but are associated with substantial long‐term toxicity. Immune checkpoint inhibitors (CPIs),
Marlène Pouthier, Nathalie Garnier, Amaury Leruste, Charlotte Rigaud, Catherine Curtillet, Stéphane Ducassou, Marilyne Poirée, Marie‐Emilie Dourthe, Cécile Pochon, Marie‐Laure Couec, Jacinthe Bonneau‐Lagacherie, Françoise Montravers, Sabah Boudjemaa, Bénédicte Jonca, Stéphanie Haouy, Thierry Leblanc, Judith Landman Parker, Mathieu Simonin   +17 more
wiley   +1 more source

Myelodysplastic Syndrome Secondary to Chimeric Antigen Receptor T-cell (CAR-T) Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma. [PDF]

Cureus
Tai W, Kim D, Dib J, Thomas J, Gopishetty S, Idogun P, Anyadibe A, Ayetoran A, Zaidi S, Balaraman S, Jaiyesimi I.   +10 more
europepmc   +1 more source